Navigation Links
Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism
Date:4/13/2009

ism Speaks. "We are incredibly grateful to Ernie Els and his family for agreeing to help spread our message of awareness and the critical importance of early diagnosis and intervention."

The new PSAs build on the success of the first round of the award-winning Autism Awareness campaign which launched in April 2006, and has received more than $178.2 million in donated media. According to Ad Council tracking surveys conducted this past September, 59% of individuals who reported seeing the ads said that autism is "very/somewhat common," and 20% of individuals who are "ad aware" have discussed autism with a doctor or pediatrician in the past six months.

Per the Ad Council model, the PSAs will run and air in advertising time and space that is donated by the media. Print advertising will be available in February.

"We are proud to continue our initiative with Autism Speaks with this wonderful series of PSAs designed to encourage parents to learn the early signs of autism," said Peggy Conlon, President & CEO of The Advertising Council. "This unique campaign, with its clear and simple message, holds great promise to help parents know the signs of autism."

"The 1 in 150 statistic is a powerful one on its own. Our goal was to couch that startling statistic in a story that pulls a viewer in so that when those odds are revealed, we have his or her full attention. By telling the story from the point of view of Ernie Els' world rather than Ben's, the communication speaks even more strongly to the people who can help with an early diagnosis - the parents," said Susan Credle, Executive Vice President and Executive Creative Director of BBDO New York.

According to the Centers for Disease Control (CDC), autism is the fastest- growing developmental disorder in the United States, with life-long consequences for individuals, family, and society. This complex brain disorder inhibits a person's
'/>"/>

SOURCE The Ad Council
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: Davis Phinney Foundation and Medtronic Raise Awareness of How to Improve Your Life Today for Those Living With Parkinsons Disease
2. Video: Participants Find New Routes, Routines on National Start! Walking Day
3. Video: New First Response(R) Fertility Test Helps Women Answer the Question: Am I Able to Get Pregnant?
4. Video: New Survey Reveals Misconceptions About Forming New Habits
5. Video: U.S. Department of Health & Human Services and Ad Council Launch National Lupus Awareness Campaign
6. Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
7. Video: Celebrities and Thousands of Walkers Unite at Nations Capitol to Raise Awareness About Seizures and Epilepsy
8. Video: Allergan Announces the LATISSE(TM) Wishes Campaign, Committing $1 Million to The Make-A-Wish Foundation(R)
9. Video: Cosmetic Procedures Up In All Ethnic Groups Except Caucasians In 2008
10. Video: Bathmate Hydropump Poised to Replace Cialis, Levitra, and Viagra
11. Video: Astrazeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...enis® Ltd. a global developer, manufacturer an...y devices for ophthalmic, surgical and aesthetic a...linical study into the efficacy of Selective Retin...he study will take place at the Tel Aviv Medical C...t Loewenstein MD. , (PRWE...
(Date:11/5/2009)...edomVOICE® proposes telecommuting as a viable ...the workplace and offers tips to business owners t... Encinitas, CA (Vocus) -- FreedomVOICE&re...X , have proposed telecommuting as a viable option...rkplace., , ,Whether we like it or not, the H1N1 v...
(Date:11/5/2009)...wswire-FirstCall/ -- Cadence Pharmaceuticals, Inc....used on in-licensing, developing and commercializi...use in the hospital setting, today reported financ...ptember 30, 2009. ,, Based upon the Priority Re...New Drug Application (NDA) for Acetavance(TM) (int...
(Date:11/5/2009)...wire-FirstCall/ -- Carriage Services, Inc. (NYSE: ... 2009, it has amended and extended its existing se...ts lenders, Bank of America and Wells Fargo. Prio...ity was scheduled to mature in April 2010. The ame...on with an accordion provision for an additional $...
(Date:11/5/2009)...ing of human diseases, scientists say , ,...of the domestic horse has been sequenced, an accom... and may help studies of human health, according t...ng access to multiple genome sequences makes it ea... By looking at the horse genome, we can better und...
Breaking Medicine News(10 mins):Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 2Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 3Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 4Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 5Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 6Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 2Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 3Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 4Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Health News:Carriage Services Amends and Extends Credit Facility 2Health News:Complete Horse Genome Sequence Revealed 2
... The Providence Service,Corporation (Nasdaq: PR...pany,s,Chief Operating Officer, has been appointed... appointment fills the vacancy left by the April 2...is, age 41, has been with Providence since its inc...
... cautious about future antibiotic resistance from ...thDay News) -- People with moderate to severe chro...le to reduce the frequency of exacerbations throug...espiratory and Critical Care Medicine , found that...
...lead to a novel technique to combat cancer, study ... -- Belgian researchers have discovered that some ...food, and this might lead to new treatments that s...cess that requires oxygen. Compared with normal ce...
.... 21 New research at West Virginia University i...product aimed at young adults is catching on. And ... Snus - touted as a socially acceptable way to sat...e Adkins of the state Division of Tobacco Preventi...
...end To Vigorously Protect Investment And Restore S... Stephen Joffe, Craig Joffe, and Alan Buckey today... U.S. Securities and Exchange Commission. The gro...rection centers in 33 states in the United States....
... general membership of the Medical,Advertising Hal... their Annual,Awards Dinner to be held February 10... Achievement Award will also be given. , The...r & Hennessey. In 1980 he left Sudler & He...
Other Medicine News:Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3
(Date:11/5/2009)... 5 Transgenomic, Inc. (O...ebcast: , , What: Transgenomic, Inc. Third...rence Call, When: Thursday, November 5, 20...p://www.transgenomic.com/events.asp?id=6, target...s.asp?id=6,>http://www.transgenomic.com/events.a...
(Date:11/5/2009)...RNewswire-FirstCall/ -- STMicroelectronics (NYSE: ...ompanies, and Mayo Clinic, a premier health-care o... for remotely monitoring patients with chronic car...omprehensive and unobtrusive solution that monitor...s and influences lifestyle and treatment choices. ...
(Date:11/4/2009)...ov. 4 Raptor Pharmaceuti...ata from a clinical trial of NGX426, the Company,s...gonist, will be presented at the 12th Internationa...uropathic Pain, to be held November 20-21, 2009 in...com/cgi-bin/prnh/20071022/NYM074LOGO ) ,, Mar...
Breaking Medicine Technology:Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast 2Remote Heart-Monitoring Platform Begins Validation 2Remote Heart-Monitoring Platform Begins Validation 3Remote Heart-Monitoring Platform Begins Validation 4Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference 2Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference 3Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference 4Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference 5Hard To Treat Diseases 28HTDS PK 29 Tender Order To Indonesia 51808 1Hard To Treat Diseases 28HTDS PK 29 Tender Order To Indonesia 51808 2Thomson Reuters Partners With Sagient Research 13050 1Thomson Reuters Partners With Sagient Research 13050 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 1NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 3
...armaceutical company Kiadis,Pharma announces today...he,last patient on its ATIR(TM) phase I/II clinica...roduct, is under development to prevent acute Graf...e reconstitution following a,mismatched bone marro...,patients were treated with no cases of grade III/...
...monstrating potential in newly diagnosed patients ...tured in two oral sessions at ASH , , - Exjad...transfused patients by significantly reducing toxi...ong-term data from major independent breast cancer...treatment strategy, Femara vs. tamoxifen , , ...
Other Medicine Technology:Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: